Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: a pilot study
- PMID: 18317009
- DOI: 10.1097/QAD.0b013e3282f470d2
Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: a pilot study
Abstract
We hypothesized that heightened systemic inflammation contributes to the increased rate of cardiovascular events in HIV-infected patients not receiving combination antiretroviral therapy. We performed a pilot trial to assess the effects of the nuclear factor-kappaB inhibitor salsalate on flow-mediated dilation of the brachial artery, a measure of endothelial function. Flow-mediated dilation significantly improved after 8 weeks of salsalate. However, hepatotoxicity occurred frequently. Research using alternative agents is warranted to examine the role of inflammation in HIV-related cardiovascular disease.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
